CN106924259A - 治疗方案 - Google Patents
治疗方案 Download PDFInfo
- Publication number
- CN106924259A CN106924259A CN201710010422.0A CN201710010422A CN106924259A CN 106924259 A CN106924259 A CN 106924259A CN 201710010422 A CN201710010422 A CN 201710010422A CN 106924259 A CN106924259 A CN 106924259A
- Authority
- CN
- China
- Prior art keywords
- subject
- composition
- agent
- receptor
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 221
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims description 548
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 542
- 239000002269 analeptic agent Substances 0.000 claims description 291
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 241
- 229960003991 trazodone Drugs 0.000 claims description 241
- 239000005557 antagonist Substances 0.000 claims description 204
- 239000003795 chemical substances by application Substances 0.000 claims description 182
- 239000012190 activator Substances 0.000 claims description 176
- 239000003937 drug carrier Substances 0.000 claims description 108
- 208000010877 cognitive disease Diseases 0.000 claims description 103
- 101800000989 Oxytocin Proteins 0.000 claims description 100
- 102400000050 Oxytocin Human genes 0.000 claims description 100
- 230000004064 dysfunction Effects 0.000 claims description 98
- 238000011282 treatment Methods 0.000 claims description 93
- 229960003638 dopamine Drugs 0.000 claims description 81
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims description 79
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 79
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims description 77
- 229960002053 flibanserin Drugs 0.000 claims description 77
- 230000001149 cognitive effect Effects 0.000 claims description 52
- 210000004556 brain Anatomy 0.000 claims description 51
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 50
- 229960002748 norepinephrine Drugs 0.000 claims description 50
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 50
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 35
- 201000001881 impotence Diseases 0.000 claims description 35
- 208000019901 Anxiety disease Diseases 0.000 claims description 31
- 230000036506 anxiety Effects 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 25
- 208000030431 Male orgasmic disease Diseases 0.000 claims description 18
- 201000000068 inhibited male orgasm Diseases 0.000 claims description 18
- 208000015421 male orgasm disease Diseases 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 206010012289 Dementia Diseases 0.000 claims description 16
- 208000021663 Female sexual arousal disease Diseases 0.000 claims description 16
- 208000014840 female orgasmic disease Diseases 0.000 claims description 13
- 201000004197 inhibited female orgasm Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 230000000994 depressogenic effect Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 9
- 208000028698 Cognitive impairment Diseases 0.000 claims description 8
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 230000006931 brain damage Effects 0.000 claims description 4
- 231100000874 brain damage Toxicity 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 230000006999 cognitive decline Effects 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- 208000003906 hydrocephalus Diseases 0.000 claims description 4
- 208000022610 schizoaffective disease Diseases 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 230000032696 parturition Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000012800 visualization Methods 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical class F* 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract description 39
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 39
- 241000282414 Homo sapiens Species 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 description 429
- -1 azoles Ketone Chemical class 0.000 description 126
- 239000000674 adrenergic antagonist Substances 0.000 description 101
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 98
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 92
- 102100024301 COMM domain-containing protein 3 Human genes 0.000 description 90
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 65
- 229960001800 nefazodone Drugs 0.000 description 65
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 61
- 229960001785 mirtazapine Drugs 0.000 description 61
- HBGWAZBZXJBYQD-UHFFFAOYSA-N amedalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 HBGWAZBZXJBYQD-UHFFFAOYSA-N 0.000 description 59
- 229950000203 amedalin Drugs 0.000 description 59
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 description 59
- 229950003015 edivoxetine Drugs 0.000 description 59
- 229950006048 manifaxine Drugs 0.000 description 59
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 description 59
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 59
- 229960004090 maprotiline Drugs 0.000 description 59
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 description 59
- 229950010561 radafaxine Drugs 0.000 description 59
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 58
- 244000194101 Ginkgo biloba Species 0.000 description 58
- 235000008100 Ginkgo biloba Nutrition 0.000 description 58
- 229950002139 talsupram Drugs 0.000 description 58
- HLOCJJORRHQDKS-UHFFFAOYSA-N cp-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 description 57
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 57
- 229950006964 tandamine Drugs 0.000 description 57
- 235000011201 Ginkgo Nutrition 0.000 description 56
- 244000141009 Hypericum perforatum Species 0.000 description 56
- 235000017309 Hypericum perforatum Nutrition 0.000 description 56
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 56
- 229950009468 ciclazindol Drugs 0.000 description 56
- OILWWIVKIDXCIB-UHFFFAOYSA-N teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 description 56
- 229950003014 teniloxazine Drugs 0.000 description 56
- YFAIJBZEDDOCAN-UHFFFAOYSA-N daledalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 YFAIJBZEDDOCAN-UHFFFAOYSA-N 0.000 description 55
- QLOOWOVVZLBYHU-VIFPVBQESA-N (2s)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine Chemical compound O1C(CC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 QLOOWOVVZLBYHU-VIFPVBQESA-N 0.000 description 54
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 53
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 53
- 229950004863 lortalamine Drugs 0.000 description 53
- 229960001255 viloxazine Drugs 0.000 description 53
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 52
- 229950004211 nisoxetine Drugs 0.000 description 52
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 description 51
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 51
- 229960001140 cyproheptadine Drugs 0.000 description 51
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 51
- 229960005417 ketanserin Drugs 0.000 description 51
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 51
- 229960005017 olanzapine Drugs 0.000 description 51
- 229960004143 tapentadol hydrochloride Drugs 0.000 description 51
- 229960002430 atomoxetine Drugs 0.000 description 50
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 50
- 229960004170 clozapine Drugs 0.000 description 50
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 50
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 50
- 229950009626 ritanserin Drugs 0.000 description 50
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 48
- 229960004431 quetiapine Drugs 0.000 description 48
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 48
- 229960001534 risperidone Drugs 0.000 description 48
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 47
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 47
- 229960004372 aripiprazole Drugs 0.000 description 47
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 47
- 229960005060 lorcaserin Drugs 0.000 description 47
- 229960003770 reboxetine Drugs 0.000 description 47
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 47
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 42
- 229960005245 asenapine Drugs 0.000 description 42
- 230000000694 effects Effects 0.000 description 40
- 108700021293 carbetocin Proteins 0.000 description 35
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 description 35
- 229960001118 carbetocin Drugs 0.000 description 35
- 230000001568 sexual effect Effects 0.000 description 32
- 235000015170 shellfish Nutrition 0.000 description 22
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229910052801 chlorine Inorganic materials 0.000 description 15
- 230000036299 sexual function Effects 0.000 description 15
- 230000035946 sexual desire Effects 0.000 description 13
- 150000002576 ketones Chemical class 0.000 description 12
- 230000037007 arousal Effects 0.000 description 11
- 230000008484 agonism Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000003340 retarding agent Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 206010057671 Female sexual dysfunction Diseases 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 206010036596 premature ejaculation Diseases 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 206010054089 Depressive symptom Diseases 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 230000002996 emotional effect Effects 0.000 description 6
- 150000002475 indoles Chemical class 0.000 description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002484 serotonin 2C antagonist Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 229960005141 piperazine Drugs 0.000 description 5
- QPUMEZIFDXYGPG-UHFFFAOYSA-N piperazine 1H-pyrrole Chemical class N1CCNCC1.N1C=CC=C1 QPUMEZIFDXYGPG-UHFFFAOYSA-N 0.000 description 5
- JADFCQKRKICRKI-UHFFFAOYSA-N quinoline;sulfane Chemical compound S.N1=CC=CC2=CC=CC=C21 JADFCQKRKICRKI-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940076134 benzene Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000003924 mental process Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- 244000018633 Prunus armeniaca Species 0.000 description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical compound [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 239000002400 serotonin 2A antagonist Substances 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 101000742062 Bos taurus Protein phosphatase 1G Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960000510 ammonia Drugs 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- ZNLKUTKJLXOFDS-UHFFFAOYSA-N azane 1-phenylpropan-1-one Chemical compound C1(=CC=CC=C1)C(=O)CC.N ZNLKUTKJLXOFDS-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 150000002221 fluorine Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229940060037 fluorine Drugs 0.000 description 2
- 230000003694 hair properties Effects 0.000 description 2
- NMMSCZRQCPXWHD-UHFFFAOYSA-N heptane;pyridine Chemical compound C1=CC=NC=C1.CCCCCCC NMMSCZRQCPXWHD-UHFFFAOYSA-N 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 2
- 229950007352 talopram Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 208000024309 orgasm disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679999P | 2012-08-06 | 2012-08-06 | |
| US61/679,999 | 2012-08-06 | ||
| CN201380052215.1A CN104884060A (zh) | 2012-08-06 | 2013-08-06 | 治疗方案 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380052215.1A Division CN104884060A (zh) | 2012-08-06 | 2013-08-06 | 治疗方案 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924259A true CN106924259A (zh) | 2017-07-07 |
Family
ID=50068530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710010422.0A Pending CN106924259A (zh) | 2012-08-06 | 2013-08-06 | 治疗方案 |
| CN201380052215.1A Pending CN104884060A (zh) | 2012-08-06 | 2013-08-06 | 治疗方案 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380052215.1A Pending CN104884060A (zh) | 2012-08-06 | 2013-08-06 | 治疗方案 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9517254B2 (ru) |
| EP (1) | EP2879680A4 (ru) |
| JP (2) | JP2015524474A (ru) |
| KR (3) | KR20200128437A (ru) |
| CN (2) | CN106924259A (ru) |
| AU (2) | AU2013299725A1 (ru) |
| BR (1) | BR112015002687A2 (ru) |
| CA (1) | CA2881388A1 (ru) |
| EA (1) | EA201590349A1 (ru) |
| HK (2) | HK1211239A1 (ru) |
| IL (1) | IL237150B (ru) |
| MX (1) | MX2015001695A (ru) |
| SG (3) | SG10201709967YA (ru) |
| WO (1) | WO2014025814A1 (ru) |
| ZA (1) | ZA201501562B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2933921A1 (en) * | 2016-06-17 | 2017-12-17 | S1 Biopharma, Inc. | Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
| CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
| WO2011146726A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4321965A1 (de) | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP2002322085A (ja) | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| CA2500831A1 (en) | 2002-10-03 | 2004-04-15 | Eric Hollander | Treatment of autism and similar disorders |
| EP1605894A2 (en) * | 2003-03-05 | 2005-12-21 | PR Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| BRPI0510074A (pt) | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
| CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| CN101568333A (zh) * | 2006-10-31 | 2009-10-28 | 詹森药业有限公司 | 广泛性发育障碍的治疗 |
| WO2008075162A2 (en) | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
| WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
| EA201170352A1 (ru) * | 2008-08-21 | 2011-08-30 | Рихтер Гедеон Нирт. | Способы лечения расстройств цнс |
| CA3037010A1 (en) * | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| WO2011140608A1 (en) | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
| US9585935B2 (en) | 2010-07-30 | 2017-03-07 | The Regents Of The University Of California | Intranasal oxytocin treatment to improve schizophrenia |
| MX354989B (es) | 2011-04-04 | 2018-03-28 | S1 Biopharma Inc | Regimenes de tratamiento. |
-
2013
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Application Discontinuation
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Application Discontinuation
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en active Application Filing
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Application Discontinuation
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
- 2015-12-10 HK HK15112183.5A patent/HK1211239A1/xx unknown
-
2016
- 2016-03-01 HK HK16102368.2A patent/HK1214505A1/zh unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
| CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
| WO2011146726A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201709967YA (en) | 2018-01-30 |
| SG10201908587PA (en) | 2019-10-30 |
| EA201590349A1 (ru) | 2015-07-30 |
| CA2881388A1 (en) | 2014-02-13 |
| AU2013299725A1 (en) | 2015-03-26 |
| JP2015524474A (ja) | 2015-08-24 |
| MX2015001695A (es) | 2015-09-28 |
| ZA201501562B (en) | 2017-11-29 |
| AU2018205121A1 (en) | 2018-07-26 |
| KR20150063039A (ko) | 2015-06-08 |
| HK1214505A1 (zh) | 2016-07-29 |
| KR20200128437A (ko) | 2020-11-12 |
| SG11201500919PA (en) | 2015-04-29 |
| IL237150A0 (en) | 2015-04-30 |
| HK1211239A1 (en) | 2016-05-20 |
| KR20230136142A (ko) | 2023-09-26 |
| JP2018150357A (ja) | 2018-09-27 |
| WO2014025814A1 (en) | 2014-02-13 |
| BR112015002687A2 (pt) | 2019-12-17 |
| US9517254B2 (en) | 2016-12-13 |
| US20150150946A1 (en) | 2015-06-04 |
| IL237150B (en) | 2018-07-31 |
| CN104884060A (zh) | 2015-09-02 |
| EP2879680A1 (en) | 2015-06-10 |
| EP2879680A4 (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113993522A (zh) | 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法 | |
| CN107847499A (zh) | 治疗神经退行性疾病的方法 | |
| CN101568362A (zh) | 治疗抑郁症的方法 | |
| TW202400135A (zh) | 包含阿替卡普蘭之組成物 | |
| JP6563998B2 (ja) | 治療計画 | |
| CN106924259A (zh) | 治疗方案 | |
| US20240009164A1 (en) | Methods and compounds for treating ulcerative colitis | |
| CA2933921A1 (en) | Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment | |
| TWI599371B (zh) | 醫藥組合物用於製備治療檳榔使用失調之藥物上的用途 | |
| WO2023272335A1 (en) | Cannabidiol formulation comprising a matrix pellet forming excipient | |
| WO2013152108A1 (en) | 5ht1a agonist for treatment of high cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1240825 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170707 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1240825 Country of ref document: HK |